Zacks: Brokerages Expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to Post -$0.25 EPS

Analysts expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to report earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.21). Pieris Pharmaceuticals reported earnings per share of ($0.21) in the same quarter last year, which would indicate a negative year-over-year growth rate of 19%. The business is expected to report its next quarterly earnings results on Monday, March 16th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.78) per share for the current year, with EPS estimates ranging from ($0.98) to ($0.65). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.22) to ($0.43). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Monday, November 11th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.18. Pieris Pharmaceuticals had a negative net margin of 107.24% and a negative return on equity of 132.02%. The firm had revenue of $15.13 million for the quarter, compared to analysts’ expectations of $6.28 million.

Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Pieris Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $4.50 price target for the company in a research note on Thursday, November 28th. ValuEngine cut Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th. William Blair reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a report on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Pieris Pharmaceuticals in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $5.50.

PIRS traded down $0.03 during trading on Wednesday, hitting $3.90. 402 shares of the company’s stock traded hands, compared to its average volume of 720,274. The company’s 50 day simple moving average is $3.60 and its two-hundred day simple moving average is $4.27. Pieris Pharmaceuticals has a 12-month low of $2.39 and a 12-month high of $6.04. The stock has a market capitalization of $212.77 million, a price-to-earnings ratio of -7.74 and a beta of 1.32.

In other Pieris Pharmaceuticals news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $4.50, for a total value of $225,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.59% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PIRS. Strs Ohio boosted its stake in shares of Pieris Pharmaceuticals by 7.5% in the 2nd quarter. Strs Ohio now owns 112,900 shares of the biotechnology company’s stock worth $530,000 after buying an additional 7,900 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Pieris Pharmaceuticals by 216.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 85,549 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 58,519 shares during the period. Fosun International Ltd lifted its stake in shares of Pieris Pharmaceuticals by 63.8% in the 2nd quarter. Fosun International Ltd now owns 364,693 shares of the biotechnology company’s stock worth $1,616,000 after purchasing an additional 142,000 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Pieris Pharmaceuticals by 3.9% in the 2nd quarter. Renaissance Technologies LLC now owns 2,168,700 shares of the biotechnology company’s stock worth $10,193,000 after purchasing an additional 80,900 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Pieris Pharmaceuticals by 25.4% in the second quarter. Parametric Portfolio Associates LLC now owns 21,177 shares of the biotechnology company’s stock worth $100,000 after buying an additional 4,290 shares during the last quarter. 51.27% of the stock is currently owned by hedge funds and other institutional investors.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Read More: Percentage Gainers

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.